Chen Lisa S, Nowak Billie J, Ayres Mary L, Krett Nancy L, Rosen Steven T, Zhang Shuxing, Gandhi Varsha
Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Biochem Pharmacol. 2009 Sep 15;78(6):583-91. doi: 10.1016/j.bcp.2009.05.019. Epub 2009 May 27.
8-Chloroadenosine (8-Cl-Ado) is a ribonucleoside analogue that is currently in clinical trial for chronic lymphocytic leukemia. Based on the decline in cellular ATP pool following 8-Cl-Ado treatment, we hypothesized that 8-Cl-ADP and 8-Cl-ATP may interfere with ATP synthase, a key enzyme in ATP production. Mitochondrial ATP synthase is composed of two major parts; F(O) intermembrane base and F1 domain, containing alpha and beta subunits. Crystal structures of both alpha and beta subunits that bind to the substrate, ADP, are known in tight binding (alpha(dp)beta(dp)) and loose binding (alpha(tp)beta(tp)) states. Molecular docking demonstrated that 8-Cl-ADP/8-Cl-ATP occupied similar binding modes as ADP/ATP in the tight and loose binding sites of ATP synthase, respectively, suggesting that the chlorinated nucleotide metabolites may be functional substrates and inhibitors of the enzyme. The computational predictions were consistent with our whole cell biochemical results. Oligomycin, an established pharmacological inhibitor of ATP synthase, decreased both ATP and 8-Cl-ATP formation from exogenous substrates, however, did not affect pyrimidine nucleoside analogue triphosphate accumulation. Synthesis of ATP from ADP was inhibited in cells loaded with 8-Cl-ATP. These biochemical studies are in consent with the computational modeling; in the alpha(tp)beta(tp) state 8-Cl-ATP occupies similar binding as ANP, a non-hydrolyzable ATP mimic that is a known inhibitor. Similarly, in the substrate binding site (alpha(dp)beta(dp)) 8-Cl-ATP occupies a similar position as ATP mimic ADP-BeF(3)(-). Collectively, our current work suggests that 8-Cl-ADP may serve as a substrate and the 8-Cl-ATP may be an inhibitor of ATP synthase.
8-氯腺苷(8-Cl-Ado)是一种核糖核苷类似物,目前正处于慢性淋巴细胞白血病的临床试验阶段。基于8-Cl-Ado处理后细胞ATP池的下降,我们推测8-Cl-ADP和8-Cl-ATP可能会干扰ATP合成酶,这是ATP产生过程中的关键酶。线粒体ATP合成酶由两个主要部分组成;内膜基部F(O)和包含α和β亚基的F1结构域。已知与底物ADP结合的α和β亚基的晶体结构处于紧密结合(α(dp)β(dp))和松散结合(α(tp)β(tp))状态。分子对接表明,8-Cl-ADP/8-Cl-ATP分别在ATP合成酶的紧密和松散结合位点占据与ADP/ATP相似的结合模式,这表明氯化核苷酸代谢物可能是该酶的功能性底物和抑制剂。计算预测与我们的全细胞生化结果一致。寡霉素是一种已确定的ATP合成酶药理学抑制剂,它减少了外源性底物产生的ATP和8-Cl-ATP,但不影响嘧啶核苷类似物三磷酸的积累。在加载8-Cl-ATP的细胞中,ADP合成ATP受到抑制。这些生化研究与计算模型一致;在α(tp)β(tp)状态下,8-Cl-ATP占据与ANP相似的结合位置,ANP是一种不可水解的ATP模拟物,是一种已知的抑制剂。同样,在底物结合位点(α(dp)β(dp)),8-Cl-ATP占据与ATP模拟物ADP-BeF(3)(-)相似的位置。总的来说,我们目前的工作表明8-Cl-ADP可能作为底物,而8-Cl-ATP可能是ATP合成酶的抑制剂。